<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        233-186-05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUZIME 750 MG INJECTION,I.M - I.V VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUROXIME SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefuzime</strong> is an antibiotic used in adults and children. It works by killing bacteria that cause infections. It belongs to a group of medicines called <em>cephalosporins. </em></p><p><strong>Cefuzime is used to treat infections of:</strong></p><p>&middot; The lungs or chest</p><p>&middot; The urinary tract</p><p>&middot; The skin and soft tissue</p><p>&middot; The abdomen</p><p><strong>Cefuzime</strong> is also used:</p><p>&middot; To prevent infections during surgery.</p><p>Your doctor may test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to <strong>Cefuzime</strong> during your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Cefuzime: </strong></p><p>&middot; <strong>If you are allergic to any cephalosporin antibiotics or any of the other </strong>ingredients of <strong>Cefuzime</strong> (listed in section 6).<strong> </strong></p><p>&middot; If you have ever had a severe allergic (<em>hypersensitive</em>) reaction to any other type of betalactam antibiotic (penicillins, monobactams and carbapenems).</p><p><strong>Tell your doctor before </strong>you start on <strong>Cefuzime</strong> if you think that this applies to you. You must not be given <strong>Cefuzime</strong>.</p><p><strong>Take special care with Cefuzime</strong></p><p>You must look out for certain symptoms such as allergic reactions, skin rashes, gastrointestinal disorders such as diarrhoea or fungal infections while you are being given <strong>Cefuzime</strong>. This will reduce the risk of possible problems. See (&lsquo;Conditions you need to look out for&rsquo;) in section 4. If you have had any allergic reaction to other antibiotics such as penicillin, you may also be allergic to <strong>Cefuzime</strong>.</p><p><strong>If you need a blood or urine test </strong></p><p><strong>Cefuzime</strong> can affect the results of urine or blood tests for sugar and a blood test known as the <em>Coombs test</em>. If you are having tests:</p><p>&middot; <strong>tell the person taking the sample </strong>that you have been given <strong>Cefuzime</strong>.</p><p><strong>Other medicines and Cefuzime</strong></p><p>Tell your doctor if you are taking any other medicines, if you&rsquo;ve started taking any recently or you start taking new ones. This includes medicines you can obtain without a prescription.</p><p>Some medicines may affect how <strong>Cefuzime</strong> works, or make it more likely that you&rsquo;ll have side effects. These include:</p><p>&middot;&nbsp;&nbsp; <strong>Aminoglycoside-type antibiotics </strong></p><p>&middot;&nbsp;&nbsp; <strong>Water tablets </strong>(diuretics), such as furosemide</p><p>&middot;&nbsp;&nbsp; <strong>Probenecid </strong></p><p>&middot;&nbsp;&nbsp; <strong>Oral anticoagulants </strong></p><p><strong>Tell your doctor </strong>if this applies to you. You may need extra check-ups to monitor your renal function while you are taking <strong>Cefuzime</strong>.</p><p><strong>Contraceptive pills </strong></p><p><strong>Cefuzime</strong> may reduce the effectiveness of the contraceptive pill. If you are taking the contraceptive pill while you are being treated with <strong>Cefuzime</strong> you also need to use a <strong>barrier method of contraception </strong>(such as condoms). Ask your doctor for advice.</p><p><strong>Pregnancy and breast-feeding and fertility </strong></p><p>Tell your doctor before you are given <strong>Cefuzime</strong>:</p><p>&middot;&nbsp;&nbsp; If you are pregnant, think you might be pregnant or are planning to become pregnant</p><p>&middot;&nbsp;&nbsp; If you are breastfeeding</p><p>Your doctor will consider the benefit of treating you with <strong>Cefuzime</strong> against the risk to your baby.</p><p><strong>Driving and using machines </strong></p><p>Don&rsquo;t drive or use machines if you do not feel well.</p><p><strong>Important information about some of the ingredients of Cefuzime </strong></p><p><strong>Cefuzime</strong> contains sodium. You need to take this into account if you are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefuzime is usually given by a doctor or nurse. </strong>It can be given as a <strong>drip </strong>(intravenous infusion) or as an <strong>injection </strong>directly into a vein or into a muscle.</p><p><strong>The usual dose </strong></p><p>The correct dose of <strong>Cefuzime</strong> for you will be decided by your doctor and depends on: the severity and type of infection, whether you are on any other antibiotics; your weight and age; how well your kidneys are working.</p><p><strong>Newborn babies (0 - 3 weeks)&nbsp; </strong></p><p><strong>For every 1 kg the baby weighs, </strong>they&rsquo;ll be given 30 to 100 mg <strong>Cefuzime</strong> per day divided in two or three doses.</p><p><strong>Babies (over 3 weeks) and children </strong></p><p><strong>For every 1 kg the baby or child weighs</strong>, they&rsquo;ll be given 30 to 100 mg of <strong>Cefuzime</strong> per day divided in three or four doses.</p><p><strong>Adults and adolescents </strong></p><p>750 mg to 1.5 g of <strong>Cefuzime</strong> per day divided into two, three or four doses. Maximum dose: 6 g per day.</p><p><strong>Patients with kidney problems </strong></p><p>If you have a kidney problem, your doctor may change your dose.</p><p><strong>Talk to your doctor </strong>if this applies to you.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 1.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Cefuzime</strong> can cause side effects, although not everybody gets them.</p><p><strong>Conditions you need to look out for &nbsp;</strong></p><p>A small number of people taking cefuroxime<strong> </strong>get an allergic reaction or potentially serious skin reaction. Symptoms of these reactions include:</p><p>&middot;&nbsp;&nbsp; <strong>Severe allergic reaction</strong>. Signs include <strong>raised and itchy rash</strong>, <strong>swelling</strong>, sometimes of the face or mouth causing <strong>difficulty in breathing</strong>.</p><p>&middot;&nbsp;&nbsp; <strong>Skin rash, </strong>which may <strong>blister</strong>, and looks like <strong>small targets </strong>(central dark spot surrounded by a paler area, with a dark ring around the edge).</p><p>&middot;&nbsp;&nbsp; <strong>A widespread rash </strong>with <strong>blisters </strong>and <strong>peeling skin. </strong>(These may be signs of <em>Stevens-Johnson syndrome </em>or <em>toxic epidermal necrolysis</em>).</p><p><strong>Other symptoms you need to be aware of while taking </strong><strong>cefuroxime include:</strong></p><p>&middot;&nbsp;&nbsp; <strong>Fungal infections </strong>on rare occasions, medicines like cefuroxime<strong> </strong>can cause an overgrowth of yeast (<em>Candida</em>) in the body which can lead to fungal infections (such as thrush). This side effect is more likely if you use cefuroxime<strong> </strong>for a long time.</p><p>&middot;&nbsp;&nbsp; <strong>Severe diarrhoea (Pseudomembranous colitis).</strong> Medicines like cefuroxime<strong> </strong>can cause inflammation of the colon (large intestine), causing severe diarrhoea, usually with blood and mucus, stomach pain, fever</p><p><strong>Contact a doctor or nurse immediately if you get any of these symptoms. </strong></p><p><strong>Common side effects </strong></p><p>These may affect <strong>up to 1 in 10 people: </strong></p><p>&middot;&nbsp;&nbsp; Injection site pain, swelling and redness along a vein.</p><p><strong>Tell your doctor </strong>if any of these are troubling you.</p><p>Common side effects that may show up in blood tests:</p><p>&middot;&nbsp;&nbsp; Increases in substances (enzymes) produced by the liver</p><p>&middot;&nbsp;&nbsp; Changes in your white blood cell count (neutropenia or eosinophilia)</p><p>&middot;&nbsp;&nbsp; Low levels of red blood cells <em>(anaemia) </em></p><p><strong>Uncommon side effects </strong></p><p>These may affect <strong>up to 1 in 100 people: </strong></p><p>&middot;&nbsp;&nbsp; Skin rash, itchy, bumpy rash (hives)</p><p>&middot;&nbsp;&nbsp; Diarrhoea, nausea, stomach pain</p><p><strong>Tell your doctor </strong>if you get any of these.</p><p>Uncommon side effects that may show up in blood tests:</p><p>&middot;&nbsp;&nbsp; Low levels of white blood cells (leucopenia)</p><p>&middot;&nbsp;&nbsp; Increase in bilirubin (a substance produced by the liver)</p><p>&middot;&nbsp;&nbsp; Positive Coomb&rsquo;s test.</p><p><strong>Other side effects </strong></p><p>Other side effects have occurred in a very small number of people but their exact frequency is unknown:</p><p>&middot;&nbsp;&nbsp; Fungal infections</p><p>&middot;&nbsp;&nbsp; High temperature (fever)</p><p>&middot;&nbsp;&nbsp; Allergic reactions</p><p>&middot;&nbsp;&nbsp; Inflammation of the colon (large intestine), causing diarrhoea, usually with blood and mucus, stomach pain</p><p>&middot;&nbsp;&nbsp; Inflammation in the kidney and blood vessels</p><p>&middot;&nbsp;&nbsp; Red blood cells destroyed too quickly (haemolytic anaemia).</p><p>&middot;&nbsp;&nbsp; Skin rash, which may blister, and looks like small targets (central dark spot surrounded by a paler area, with a dark ring around the edge) <em>erythema multiformae. </em></p><p><strong>Tell your doctor </strong>if you get any of these side effects that may show up in blood tests:</p><p>&middot;&nbsp;&nbsp; Decrease in number of blood platelets (cells that help blood to clot - thrombocytopenia)</p><p>&middot;&nbsp;&nbsp; Increase in levels of urea nitrogen and serum creatinine in the blood.</p><p><strong>If you get any side effects, tell your doctor or pharmacist. </strong>This includes any possible side effects not listed in this leaflet.</p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><p><strong>Fax:</strong>&nbsp;+966-11-205-7662</p><p><strong>Call NPC at</strong>&nbsp;+966-11-2038222,&nbsp;</p><p><strong>Exts:</strong>&nbsp;2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong>&nbsp;8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong>&nbsp;www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefuzime</strong> is for use in hospital only and the expiry date and storage instructions stated on the vial label and carton are for the doctor, nurse or pharmacist&rsquo;s information. The doctor, pharmacist or nurse will make up your medicine.</p><p>-&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp; Do not use <strong>Cefuzime</strong> after the expiry date which is stated on the carton and on the vial label.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cefuroxime. Each vial contains 500mg, or 750mg of cefuroxime (as cefuroxime sodium).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cefuzime 500mg or 750mg are available in packs of 1 vial or 10 vials each.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                29/10/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>سيفوزيم</strong> هو مضاد حيوي يستخدم من قبل البالغين والأطفال. يعمل عن طريق القضاء على البكتيريا التي تسبب العدوى. ينتمي إلى مجموعة من الأدوية تعرف باسم السيفالوسبورينات.</p><p><strong>يستخدم </strong><strong>سيفوزيم لعلاج عدوى:</strong></p><p><strong>&middot; </strong>الرئتين أو الصدر</p><p><strong>&middot; </strong>الجهاز البولي</p><p><strong>&middot; </strong>الجلد أو النسيج الرخو</p><p><strong>&middot; </strong>البطن</p><p>يستخدم أيضاً <strong>سيفوزيم:</strong></p><p><strong>&middot; </strong>للوقاية من حدوث عدوى أثناء العملية الجراحية</p><p>قد يلجأ طبيبك المعالج إلى اختبار نوع البكتيريا المسببة للعدوى ومراقبتها إذا كانت البكتيريا حساسة تجاه <strong>سيفوزيم</strong><strong> </strong><strong>&nbsp;</strong>أثناء فترة العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عليك عدم استعمال سيفوزيم في الحالات التالية:</strong></p><p><strong>&middot; </strong><strong>إذا كنت تعاني من الحساسية</strong> تجاه <strong>أياً من المضادات الحيوية من مجموعة السيفالوسبورينات أو تجاه</strong> المواد الأخرى الموجودة في <strong>سيفوزيم </strong>(المذكورة في بند رقم 6).</p><p><strong>&middot; </strong>&nbsp;إذا عانيت مسبقاً من تفاعلات تحسسية شديدة (فرط الحساسية) تجاه أي نوع من مضادات بيتا لاكتاماز (بنسلين، مونوباكتامات وكاربابيمينات)</p><p><strong>يرجى منك إخبار طبيبك المعالج</strong> قبل أن يتم إعطائك <strong>سيفوزيم </strong>إذا كنت تعتقد بأن ما ذكر أعلاه ينطبق عليك. &nbsp;في هذه الحالة يجب أن لا يعطى لك <strong>سيفوزيم</strong>.</p><p><strong>تحذيرات خاصة مع سيفوزيم</strong></p><p>يجب عليك الانتباه لبعض الأعراض في أثناء إعطائك <strong>سيفوزيم</strong> على سبيل المثال التفاعلات التحسسية، طفح الجلدي، اضطرابات المعدية المعوية بما في ذلك الإسهال أو العدوى الفطرية. مما سوف يقلل من خطر حدوث المشاكل المحتملة. انظر (&quot;الحالات التي يجب أن تكون على دراية بها&quot;) في بند رقم 4. إذا عانيت مسبقاً من أية تفاعلات تحسسية تجاه المضادات الحيوية الأخرى على سبيل المثال بنسلين، فقد تكون تعاني أيضاً من الحساسية تجاه <strong>سيفوزيم</strong>.</p><p><strong>إذا كنت بحاجة لإجراء اختبار الدم أو البول </strong></p><p>من الممكن أن يؤثر <strong>سيفوزيم </strong>على نتائج اختبارات البول أو الدم &nbsp;لفحص السكر واختبار الدم الذي يعرف باسم اختبار كومب. إذا كنت تخضع لإجراء أحد الاختبارات:</p><p><strong>&middot; </strong>&nbsp;<strong>يرجى إخبار الشخص المسؤول في أخذ العينة منك </strong>بأنك قد تلقيت علاجاً مع<strong> سيفوزيم.</strong></p><p><strong>تناول الأدوية الأخرى بالتزامن مع سيفوزيم</strong></p><p>يرجى منك إخبار طبيبك المعالج إذا كنت تتناول أية أدوية أخرى، إذا كنت قد بدأت بتناول أية أدوية قد تناولتها مؤخراً أو إذا كنت بدأت بتناول أدوية جديدة. بما في ذلك الأدوية التي يتم صرفها من دون وصفة طبية.</p><p>بعض الأدوية قد تؤثر على آلية عمل <strong>سيفوزيم</strong>، أو يجعلك أكثر عرضة لحدوث التأثيرات الجانبية. بما في ذلك:</p><p><strong>&middot; </strong><strong>أمينوجليكوسيد نوع من أنواع المضادات الحيوية</strong></p><p><strong>&middot; </strong><strong>مدرات البول، على سبيل المثال فوروسيميد</strong></p><p><strong>&middot; </strong><strong>بروبنيسيد</strong></p><p><strong>&middot; </strong><strong>مضادات التخثر الفموية</strong></p><p><strong>يرجى منك إخبار</strong> <strong>طبيبك المعالج</strong> إذا كان مما ذكر أعلاه ينطبق عليك.فقد تكون بحاجة إلى المزيد من الفحوصات لمراقبة وظائف الكلى في أثناء تلقي العلاج مع <strong>سيفوزيم</strong>.</p><p><strong>حبوب منع الحمل</strong></p><p>قد يقلل <strong>سيفوزيم</strong> من فعالية حبوب منع الحمل. إذا كنت تتناولين حبوب منع الحمل في أثناء تلقي العلاج مع استعمال <strong>سيفوزيم</strong> فقد تكونين بحاجة إلى استعمال <strong>إحدى طرق الأغشية الحاجزة لمنع الحمل</strong> (على سبيل المثال الواقي الذكري). يرجى منك استشارة طبيبك المعالج للحصول على النصيحة.</p><p><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong></p><p>يرجى منك إخبار طبيبك المعالج قبل أن يتم إعطائك <strong>سيفوزيم</strong>:</p><p><strong>&middot; </strong>إذا كنت حاملاً، &nbsp;تعتقدين بأنك حاملاً، أو تخططين بأن تصبحين حاملاً</p><p><strong>&middot; </strong>إذا كنت ترضعين طفلك رضاعة طبيعية</p><p>سوف يأخذ طبيبك المعالج بعين الاعتبار مدى الفائدة المرجوة من العلاج مع <strong>سيفوزيم </strong>والمخاطر المحتملة التي سوف يتعرض لها الطفل.</p><p><strong>القيادة وتشغيل الآلات</strong></p><p>لا تقود أو تشغل الآلات إذا كنت تشعر بأنك لست على مايرام.</p><p><strong>معلومات هامة حول معظم المكونات في سيفوزيم</strong></p><p>يحتوي <strong>سيفوزيم</strong> على الصوديوم. يجب عليك أخذ ذلك بعين الاعتبار في حال كنت تتبع حمية غذائية منخفضة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>عادة ما يتم إعطائك </strong><strong>سيفوزيم</strong><strong>&nbsp; بواسطة الطبيب المعالج أو الممرض</strong>. من الممكن أن يعطى <strong>عن طريق التنقيط </strong>(التسريب الوريدي) أو <strong>بالحقن</strong> مباشرة في الوريد أو في العضلات.</p><p><strong>الجرعة الاعتيادية </strong></p><p>سوف يتم تحديد الجرعة الصحيحة من <strong>سيفوزيم</strong> من قبل طبيبك المعالج اعتماداً على: شدة ونوع العدوى، ما إذا كنت تتلقى العلاج مع مضادات حيوية أخرى، وزنك وعمرك، كفاءة عمل الكلى لديك.</p><p><strong>الأطفال حديثي الولادة (المواليد الجدد حتى عمر3 أسابيع)</strong><strong><u> </u></strong></p><p><strong>&nbsp;لكل 1 كيلوغرام من وزن الطفل</strong>، سوف يعطى لهم من 30 إلى 100 ملغم من <strong>سيفوزيم </strong>يومياً مقسمة على&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;2 أو 3 جرعات منفصلة.</p><p><strong>الرضع (بعمر أكبر من 3 أسابيع) والأطفال</strong></p><p><strong>&nbsp;لكل 1 كيلوغرام من وزن الطفل</strong>، سوف يعطى لهم من 30 إلى 100 ملغم من <strong>سيفوزيم </strong>يومياً مقسمة على&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;3 أو 4 جرعات منفصلة.</p><p><strong>البالغون والمراهقين</strong></p><p>يتراوح مقدار الجرعة من 750 ملغم إلى 1,5 غرام من <strong>سيفوزيم</strong> يومياً مقسمة على 2، 3 أو 4 جرعات منفصلة. يبلغ مقدار الجرعة القصوى: 6 غرام يومياً.</p><p><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p>قد يلجأ طبيبك المعالج إلى تغيير مقدار الجرعة المعطاة لك، إذا كنت تعاني من مشاكل في الكلى.</p><p><strong>يرجى منك التحدث إلى طبيبك المعالج</strong> إذا كنت تعاني من مشاكل في الكلى.</p><p><strong>يرجى منك استشارة طبيبك المعالج&nbsp; أو الصيدلي الذي تتعامل معه إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يسبب <strong>سيفوزيم</strong> تأثيرات جانبية، ولكن على الرغم من ذلك قد لا تحدث لكل شخص.</p><p><strong>الحالات التي يجب أن تكون على دراية بها</strong></p><p>هناك عدد قليل من الأشخاص الذين أصيبوا بتفاعلات تحسسية أو تفاعلات جلدية التي قد تكون خطيرة أثناء فترة استعمال سيفوروكسيم. تتضمن أعراض هذه التفاعلات على:</p><p><strong>&middot; </strong><strong>تفاعلات تحسسية حادة</strong>. تتضمن العلامات على <strong>طفح جلدي بارز ومصحوب بحكة</strong>، <strong>تورم</strong>، وبعض الأحيان في الوجه أو الفم مسبباً <strong>صعوبة في التنفس</strong></p><p><strong>&middot; </strong><strong>طفح جلدي</strong>، الذي قد يظهر على شكل <strong>تقرحات </strong>(بقعة داكنة في الوسط محاطة بمنطقة شاحبة اللون، مع حلقة داكنة حول الحافة).</p><p><strong>&middot; </strong><strong>طفح جلدي </strong><strong>منتشر</strong> على نطاق واسع مع <strong>تقرحات</strong> <strong>وتقشر الجلد</strong>. (قد تكون علامات لمتلازمة ستيفن جونسن أو انحلال البشرة السمي التنخري)</p><p><strong>أعراض أخرى يجب عليك الانتباه إليها أثناء إعطائك سيفوزيم بما في ذلك:</strong></p><p><strong>&middot; </strong><strong>عدوى فطرية</strong> نادرة الحدوث، من الممكن أن تسبب الأدوية على سبيل المثال سيفوروكسيم فرط نمو الخميرة (كانديدا) في الجسم مما قد يؤدي إلى حدوث العدوى الفطرية (على سبيل المثال داء القلاع). تزيد احتمالية حدوث هذا التأثير الجانبي عند استعمال سيفوروكسيم لفترة زمنية طويلة.</p><p><strong>&middot; </strong><strong>إسهال حاد (التهاب القولون الغشائي الكاذب).</strong> قد تتسبب الأدوية مثل سيفوروكسيم في حدوث التهاب القولون (الأمعاء الغليظة)، مما يؤدي إلى الإصابة بالإسهال الحاد، المصحوب عادة بخروج الدم والمخاط وآلام في المعدة والحمى.</p><p><strong>يرجى منك التواصل مع طبيبك المعالج أو الممرض على الفور إذا تعرضت لأي من تلك الأعراض.</strong></p><p><strong>التأثيرات الجانبية الشائعة</strong></p><p>قد تؤثر هذه التأثيرات على ما قد <strong>يصل إلى شخص واحد من كل 10 أشخاص:</strong></p><p><strong>&middot; </strong>شعور بالألم في موضع الحقن، تورم واحمرار على طول الوريد.</p><p><strong>يرجى منك إخبار طبيبك المعالج</strong> إذا أصبحت هذه التأثيرات تثير قلقك.</p><p>التأثيرات الجانبية الشائعة التي قد تظهر في فحوصات الدم:</p><p><strong>&middot; </strong>ارتفاع المواد (انزيمات) التي ينتجها الكبد.</p><p><strong>&middot; </strong>تغيرات في تعداد خلايا الدم البيضاء (قلة العدلات أو فرط الحمضيات)</p><p><strong>&middot; </strong>انخفاض مستويات خلايا الدم الحمراء (فقر الدم)</p><p><strong>التأثيرات الجانبية الغير شائعة </strong></p><p>قد تؤثرعلى ما قد <strong>يصل إلى شخص واحد من كل 100 أشخاص:</strong></p><p><strong>&middot; </strong>طفح جلدي، حكة، طفح جلدي مصحوب بظهور النتوءات (الشرى)</p><p><strong>&middot; </strong>إسهال، غثيان، ألم في المعدة</p><p><strong>يرجى منك إخبار طبيبك المعالج</strong> إذا تعرضت لأي من تلك الأعراض.</p><p>التأثيرات الجانبية الغير شائعة التي قد تظهر في فحوصات الدم:</p><p><strong>&middot; </strong>انخفاض مستويات خلايا الدم البيضاء.</p><p><strong>&middot; </strong>زيادة البيليروبين (مادة تنتج عن طريق الكبد)</p><p><strong>&middot; </strong>نتائج إيجابية زائفة لاختبار كومب.</p><p><strong>تأثيرات جانبية أخرى</strong></p><p>لقد حدثت التأثيرات الجانبية الأخرى لدى عدد قليل من الأشخاص ولكن معدل تكرار حدوثها الفعلي غير معروف:</p><p><strong>&middot; </strong>عدوى فطرية</p><p><strong>&middot; </strong>ارتفاع درجة الحرارة (حمى)</p><p><strong>&middot; </strong>تفاعلات تحسسية</p><p><strong>&middot; </strong>التهاب القولون (الأمعاء الغليظة)، مسبباً الإسهال، عادة ما يكون مصحوب بظهور الدم أو المخاط، ألم في المعدة</p><p><strong>&middot; </strong>التهاب الكلى والأوعية الدموية</p><p><strong>&middot; </strong>تلف كريات الدم الحمراء بسرعة كبيرة (فقر الدم الانحلالي)</p><p><strong>&middot; </strong>طفح جلدي، الذي قد يظهر على شكل تقرحات (بقعة داكنة في الوسط محاطة بمنطقة شاحبة اللون، مع حلقة داكنة حول الأطراف) حمامى متعددة الأشكال.</p><p><strong>يرجى منك إخبار طبيبك المعالج</strong> إذا تعرضت لأي من تلك الأعراض.</p><p>التأثيرات الجانبية التي قد تظهر في فحوصات الدم:</p><p><strong>&middot; </strong>انخفاض عدد الصفائح الدموية (الخلايا التي تساعد على تخثر الدم)</p><p><strong>&middot; </strong>زيادة مستويات نيتروجين يوريا الدم ومصل الكرياتينين في الدم</p><p><strong>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه.</strong> إذا تعرضت لأي من التأثيرات الجانبية بما في ذلك التأثيرات الجانبية المحتمل حدوثها ولم تذكر في هذه النشرة.</p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong><br /><strong>&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس:</strong> 7662-205-11-966+</p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: </strong>2038222-11-966+<strong>&nbsp; </strong></p><p><strong>وصلة هاتف:</strong>2340-2334-2354-2353-2356-23<strong>17</strong></p><p><strong>الهاتف المجاني: </strong>8002490000</p><p><strong>البريد الإلكتروني:</strong><strong> </strong>&nbsp;npc.drug@sfda.gov.sa</p><p><strong>الموقع الإلكتروني:</strong> www.sfda.gov.sa/npc</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>إن </strong><strong>سيفوزيم </strong>مخصص للاستعمال فقط داخل المستشفى وظروف الحفظ وتاريخ الصلاحية هي فقط من اختصاص الطبيب المعالج، الممرض أو الصيدلي الذي تتعامل معه.</p><p><strong>-&nbsp; </strong>يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p><strong>-&nbsp; </strong>يجب عدم استعمال <strong>سيفوزيم </strong>بعد تاريخ انتهاء الصلاحية المذكور على العبوة&nbsp; والملصق الداخلي للزجاجة .</p><p><strong>-&nbsp; </strong>يحفظ في درجة حرارة أقل من 30&deg;م.</p><p><strong>-&nbsp; </strong>يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيفوروكسيم. تحتوي كل زجاجة على 500 ملغم، أو 750 ملغم من سيفوروكسيم &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(على هيئة سيفوروكسيم الصوديوم)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            يتوفر سيفوزيم  500ملغم أو 750 ملغم في عبوات تحتوي على زجاجة واحدة أو 10 زجاجات
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            29-10-2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefuzime 750mg Sterile Powder for Solution for I.M. /I.V. Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item No.	Material Name	Scale (mg/vial)
		
	Active Ingredient:	
1.		Cefuroxime Sodium, sterile	789.00
	Equivalent to Cefuroxime	750.00

For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile Powder for Solution for I.M. /I.V. Injection
Description: White to faintly yellow crystalline powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Cefuzime</strong> is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth) (see sections 4.4 and 5.1).</p><p>&sect; Community acquired pneumonia</p><p>&sect; Acute exacerbations of chronic bronchitis</p><p>&sect; Complicated urinary tract infections, including pyelonephritis</p><p>&sect; Soft-tissue infections: cellulitis, erysipelas and wound infections</p><p>&sect; Intra-abdominal infections (see section 4.4)</p><p>&sect; Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)</p><p>In the treatment and prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong>Table 1. Adults and children &ge; 40 kg</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:700px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia and acute exacerbations of chronic bronchitis</p></td><td rowspan="3" style="vertical-align:top"><p>750 mg every 8 hours</p><p>(intravenously or intramuscularly)</p></td></tr><tr><td style="vertical-align:top"><p>Soft-tissue infections: cellulitis, erysipelas and wound infections.</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections, including pyelonephritis</p></td><td style="vertical-align:top"><p>1.5 g every 8 hours</p><p>(intravenously or intramuscularly)</p></td></tr><tr><td style="vertical-align:top"><p>Severe infections</p></td><td style="vertical-align:top"><p>750 mg every 6 hours (intravenously)</p><p>1.5 g every 8 hours (intravenously)</p></td></tr><tr><td style="vertical-align:top"><p>Surgical prophylaxis for gastrointestinal, gynaecological surgery (including caesarean section) and orthopaedic operations</p></td><td style="vertical-align:top"><p>1.5 g with the induction of anaesthesia. This may be supplemented with two 750 mg doses (intramuscularly) after 8 hours and 16 hours</p></td></tr><tr><td style="vertical-align:top"><p>Surgical prophylaxis for cardiovascular and oesophageal operations</p></td><td style="vertical-align:top"><p>1.5 g with induction of anaesthesia followed by 750 mg (intramuscularly) every 8 hours for a further 24 hours</p></td></tr></tbody></table><p><strong>Table 2. Children &lt; 40 kg</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:719px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Infants and toddlers &gt; 3 weeks and children &lt; 40 kg</strong></p></td><td style="vertical-align:top"><p><strong>Infants (birth to 3 weeks)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td><td rowspan="4" style="vertical-align:top"><p>30 to 100 mg/kg/day (intravenously) given as 3 or 4 divided doses; a dose of 60 mg/kg/day is appropriate for most infections</p></td><td rowspan="4" style="vertical-align:top"><p>30 to 100 mg/kg/day (intravenously) given as 2 or 3 divided doses (see section 5.2)</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections, including pyelonephritis</p></td></tr><tr><td style="vertical-align:top"><p>Soft-tissue infections: cellulitis, erysipelas and wound infections</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr></tbody></table><p><strong>Renal impairment</strong></p><p>Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion.</p><p><strong>Table 3. Recommended doses for cefuroxime in renal impairment</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:715px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top"><p><strong>T<sub>1/2&nbsp;</sub>(hrs)</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 20 mL/min/1.73 m<sup>2</sup></p></td><td style="vertical-align:top"><p>1.7&ndash;2.6</p></td><td style="vertical-align:top"><p>It is not necessary to reduce the standard dose (750 mg to 1.5 g three times daily).</p></td></tr><tr><td style="vertical-align:top"><p>10-20 mL/min/1.73 m<sup>2</sup></p></td><td style="vertical-align:top"><p>4.3&ndash;6.5</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10 mL/min/1.73 m<sup>2</sup></p></td><td style="vertical-align:top"><p>14.8&ndash;22.3</p></td><td style="vertical-align:top"><p>750 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>3.75</p></td><td style="vertical-align:top"><p>A further 750 mg dose should be given intravenously or intramuscularly at the end of each dialysis; in addition to parenteral use, cefuroxime sodium can be incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 litres of dialysis fluid).</p></td></tr><tr><td style="vertical-align:top"><p>Patients in renal failure on continuous arteriovenous haemodialysis (CAVH) or high-flux haemofiltration (HF) in intensive therapy units</p></td><td style="vertical-align:top"><p>7.9&ndash;12.6 (CAVH)</p><p>1.6 (HF)</p></td><td style="vertical-align:top"><p>750 mg twice daily; for low-flux haemofiltration follow the dosage recommended under impaired renal function.</p></td></tr></tbody></table><p><strong>Hepatic impairment</strong></p><p>Cefuroxime is primarily eliminated by the kidney. In patients with hepatic dysfunction this is not expected to affect the pharmacokinetics of cefuroxime.</p><p><strong><u>Method of administration</u></strong></p><p><strong>Cefuzime</strong> should be administered by intravenous injection over a period of 3 to 5 minutes directly into a vein or via a drip tube or infusion over 30 to 60 minutes, or by deep intramuscular injection.</p><p>For instructions on reconstitution and preparation of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1.
	Patients with known hypersensitivity to cephalosporin antibiotics.
	History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity reactions</u></strong></p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p><strong><u>Concurrent treatment with potent diuretics or aminoglycosides</u></strong></p><p>Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as furosemide or aminoglycosides. Renal impairment has been reported during use of these combinations. Renal function should be monitored in the elderly and those with known pre-existing renal impairment (see section 4.2).</p><p><strong><u>Overgrowth of non-susceptible microorganisms</u></strong></p><p>Use of cefuroxime may result in the overgrowth of&nbsp;<em>Candida.</em>&nbsp;Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and&nbsp;<em>Clostridium difficile</em>), which may require interruption of treatment (see section 4.8).</p><p>Antibacterial agent&ndash;associated pseudomembranous colitis has been reported with use of cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for&nbsp;<em>Clostridium difficile</em>&nbsp;should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p><strong><u>Intra-abdominal infections</u></strong></p><p>Due to its spectrum of activity, cefuroxime is not suitable for the treatment of infections caused by Gram-negative non-fermenting bacteria (see section 5.1).</p><p><strong><u>Interference with diagnostic tests</u></strong></p><p>The development of a positive Coomb&#39;s Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).</p><p>Slight interference with copper reduction methods (Benedict&#39;s, Fehling&#39;s, Clinitest) may be observed. However, this should not lead to false-positive results, as may be experienced with some other cephalosporins.</p><p>As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime sodium.</p><p><strong><u>Important information about excipients</u></strong></p><p><strong>Cefuzime </strong>powder for solution for injection and infusion contains sodium. This should be considered for patients who are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefuroxime may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.</p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenicid is not recommended. Concurrent administration of probenecid prolongs the excretion of the antibiotic and produces an elevated peak serum level.</p><p><strong><u>Potential nephrotoxic drugs and loop diuretics</u></strong></p><p>High-dosage treatments with cephalosporins should be carried out with caution on patients who are taking strong-acting diuretics (such as furosemide) or potential nephrotoxic preparations (such as aminoglycoside antibiotics), since impairment of renal function through such combinations cannot be ruled out.</p><p><strong><u>Other Interactions</u></strong></p><p>Determination of blood/plasma glucose levels: refer to section 4.4.</p><p>Concomitant use with oral anticoagulants may give rise to increased international normalised ratio (INR).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>There are limited amounts of data from the use of cefuroxime in pregnant women. Studies in animals have shown no reproductive toxicity (see section 5.3). Cefuroxime should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p>Cefuroxime has been shown to cross the placenta and attain therapeutic levels in amniotic fluid and cord blood after intramuscular or intravenous dose to the mother.</p><p><strong><u>Breastfeeding</u></strong></p><p>Cefuroxime is excreted in human milk in small quantities. Adverse reactions at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from cefuroxime therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><strong><u>Fertility</u></strong></p><p>There are no data on the effects of cefuroxime sodium on fertility in humans. Reproductive studies in animals have shown no effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of cefuroxime on the ability to drive and use machines have been performed. However, based on known adverse reactions, cefuroxime is unlikely to have an effect on the ability to drive and use machines.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are neutropenia, eosinophilia, transient rise in liver enzymes or bilirubin, particularly in patients with pre-existing liver disease, but there is no evidence of harm to the liver and injection site reactions.</p><p>The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data for calculating incidence are not available. In addition the incidence of adverse reactions associated with cefuroxime sodium may vary according to the indication.</p><p>Data from clinical trials were used to determine the frequency of very common to rare adverse reactions. The frequencies assigned to all other adverse reactions (i.e. those occurring at &lt;1/10,000) were mainly determined using post-marketing data, and refer to a reporting rate rather than a true frequency.</p><p>Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for the classification of frequency: very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10; uncommon &ge; 1/1,000 to &lt; 1/100; rare &ge; 1/10,000 to &lt; 1/1,000; very rare &lt; 1/10,000 and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:700px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Infections and infestations</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><em>Candida&nbsp;</em>overgrowth, overgrowth of&nbsp;<em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td><td style="vertical-align:top"><p>neutropenia, eosinophilia, decreased haemoglobin concentration</p></td><td style="vertical-align:top"><p>leukopenia, positive Coomb&#39;s test</p></td><td style="vertical-align:top"><p>thrombocytopenia, haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p><u>Immune system disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>drug fever, interstitial nephritis, anaphylaxis, cutaneous vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>gastrointestinal disturbance</p></td><td style="vertical-align:top"><p>pseudomembranous colitis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td><td style="vertical-align:top"><p>transient rise in liver enzymes</p></td><td style="vertical-align:top"><p>transient rise in bilirubin</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>skin rash, urticaria and pruritus</p></td><td style="vertical-align:top"><p>erythema multiforme, toxic epidermal necrolysis and Stevens-Johnson syndrome, angioneurotic oedema</p></td></tr><tr><td style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>elevations in serum creatinine, elevations in blood urea nitrogen and decreased creatinine clearance (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td><td style="vertical-align:top"><p>injection site reactions which may include pain and thrombophlebitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Description of selected adverse reactions</em></p><p>Cephalosporins as a class tend to be absorbed onto the surface of red cell membranes and react with antibodies directed against the drug to produce a positive Coomb&#39;s test (which can interfere with cross matching of blood) and very rarely haemolytic anaemia.</p><p>Transient rises in serum liver enzymes or bilirubin have been observed which are usually reversible.</p><p>Pain at the intramuscular injection site is more likely at higher doses. However it is unlikely to be a cause for discontinuation of treatment.</p></td></tr></tbody></table><p><strong><u>Paediatric population</u></strong></p><p>The safety profile for cefuroxime sodium in children is consistent with the profile in adults.</p><p><strong><u>To report any side effect(s)</u></strong><strong><u>:</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4).</p><p>Serum levels of cefuroxime can be reduced by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> antibacterials for systemic use, second-generation cephalosporins, ATC code: J01DC02</p><p><strong><u>Mechanism of action</u></strong></p><p>Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><strong><u>Mechanism of resistance</u></strong></p><p>Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:</p><p>&sect; hydrolysis by beta-lactamases including (but not limited to) extended-spectrum beta-lactamases (ESBLs), and Amp-C enzymes, that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species;</p><p>&sect; reduced affinity of penicillin-binding proteins for cefuroxime;</p><p>&sect; outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;</p><p>&sect; bacterial efflux pumps.</p><p>Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime. Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.</p><p><strong><u>Cefuroxime sodium breakpoints</u></strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:693px"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Breakpoints (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><u>Susceptible</u></p></td><td style="vertical-align:top"><p><u>Resistant</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em><sup>1</sup></p></td><td style="vertical-align:top"><p>&le;8<sup>2</sup></p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em>&nbsp;spp.</p></td><td style="vertical-align:top"><p>Note<sup>3</sup></p></td><td style="vertical-align:top"><p>Note<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>A, B, C and G</p></td><td style="vertical-align:top"><p>Note<sup>4</sup></p></td><td style="vertical-align:top"><p>Note<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&le;0.5</p></td><td style="vertical-align:top"><p>&gt;1</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>(other)</p></td><td style="vertical-align:top"><p>&le;0.5</p></td><td style="vertical-align:top"><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&le;1</p></td><td style="vertical-align:top"><p>&gt;2</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&le;4</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>1</sup></p></td><td style="vertical-align:top"><p>&le;4<sup>5</sup></p></td><td style="vertical-align:top"><p>&gt;8<sup>5</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1&nbsp;</sup></strong>The cephalosporin breakpoints for&nbsp;<em>Enterobacteriaceae</em>&nbsp;will detect all clinically important resistance mechanisms (including ESBL and plasmid mediated AmpC). Some strains that produce beta-lactamases are susceptible or intermediate to 3<sup>rd</sup>&nbsp;or 4<sup>th</sup>&nbsp;generation cephalosporins with these breakpoints and should be reported as found, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purposes.</p><p><sup>2</sup>&nbsp;Breakpoint relates to a dosage of 1.5 g &times; 3 and to&nbsp;<em>E. coli, P. mirabilis</em>&nbsp;and&nbsp;<em>Klebsiella</em>&nbsp;spp. only</p><p><sup>3</sup>&nbsp;Susceptibility of staphylococci to cephalosporins is inferred from the methicillin susceptibility except for ceftazidme and cefixime and ceftibuten, which do not have breakpoints and should not be used for staphylococcal infections.</p><p><sup>4</sup>&nbsp;The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.</p><p><sup>5</sup>&nbsp;Breakpoints apply to daily intravenous dose of 750 mg &times; 3 and a high dose of at least 1.5 g &times; 3.</p></td></tr></tbody></table><p><strong><u>Microbiological susceptibility</u></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is known and the utility of the agent in at least some types of infections is questionable.</p><p>Cefuroxime is usually active against the following microorganisms&nbsp;<em>in vitro</em>.</p><table border="1" cellspacing="0" cellpadding="0" style="width:693px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Staphylococcus aureus (methicillin-suscpetible)&nbsp;</em>$</p><p><em>Streptococcus pyogenes</em></p><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Microorganisms for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Streptococcus pneumoniae</em></p><p><em>Streptococcus mitis&nbsp;</em>(viridans group)</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Citrobacter&nbsp;</em>spp. not including<em>&nbsp;C. freundii</em></p><p><em>Enterobacter&nbsp;</em>spp. not including<em>&nbsp;E. aerogenes&nbsp;</em>and&nbsp;<em>E. cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus&nbsp;</em>spp. not including<em>&nbsp;P. penneri and P. Vulgaris</em></p><p><em>Providencia</em>&nbsp;spp.</p><p><em>Salmonella&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Peptostreptococcus</em>&nbsp;spp.</p><p><em>Propionibacterium</em>&nbsp;spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Fusobacterium&nbsp;</em>spp.</p><p><em>Bacteroides&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter&nbsp;</em>spp.</p><p><em>Burkholderia cepacia</em></p><p><em>Campylobacter&nbsp;</em>spp.</p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Morganella morganii</em></p><p><em>Proteus penneri</em></p><p><em>Proteus vulgaris</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia marcescens</em></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Bacteroides fragilis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia&nbsp;</em>spp.</p><p><em>Mycoplasma</em>&nbsp;spp.</p><p><em>Legionella</em>&nbsp;spp.</p></td></tr></tbody></table><p>$ All methicillin-resistant&nbsp;<em>S. aureus</em>&nbsp;are resistant to cefuroxime.</p><p><em>In vitro</em>&nbsp;the activities of cefuroxime sodium and aminoglycoside antibiotics in combination have been shown to be at least additive with occasional evidence of synergy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>After intramuscular (IM) injection of cefuroxime to normal volunteers, the mean peak serum concentrations ranged from 27 to 35 &micro;g/mL for a 750 mg dose and from 33 to 40 &micro;g/mL for a 1000 mg dose, and were achieved within 30 to 60 minutes after administration. Following intravenous (IV) doses of 750 and 1500 mg, serum concentrations were approximately 50 and 100 &micro;g/mL, respectively, at 15 minutes.</p><p>AUC and C<sub>max</sub>&nbsp;appear to increase linearly with increase in dose over the single dose range of 250 to 1000 mg following IM and IV administration. There was no evidence of accumulation of cefuroxime in the serum from normal volunteers following repeat intravenous administration of 1500 mg doses every 8 hours.</p><p><strong><u>Distribution</u></strong></p><p>Protein binding has been stated as 33 to 50%, depending on the methodology used. The average volume of distribution ranges from 9.3 to 15.8 L/1.73 m<sup>2</sup>&nbsp;following IM or IV administration over the dosage range of 250 to 1000 mg. Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humour. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.</p><p><strong><u>Biotransformation</u></strong></p><p>Cefuroxime is not metabolised.</p><p><strong><u>Elimination</u></strong></p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. The serum half-life after either intramuscular or intravenous injection is approximately 70 minutes. There is an almost complete recovery (85 to 90%) of unchanged cefuroxime in urine within 24 hours of administration. The majority of the cefuroxime is excreted within the first 6 hours. The average renal clearance ranges from 114 to 170 mL/min/1.73 m<sup>2</sup>&nbsp;following IM or IV administration over the dosage range of 250 to 1000 mg.</p><p><strong><u>Special patient populations</u></strong></p><p><strong>Gender</strong></p><p>No differences in the pharmacokinetics of cefuroxime were observed between males and females following a single IV bolus injection of 1000 mg of cefuroxime as the sodium salt.</p><p><strong>Elderly</strong></p><p>Following IM or IV administration, the absorption, distribution and excretion of cefuroxime in elderly patients are similar to younger patients with equivalent renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in cefuroxime dose selection, and it may be useful to monitor renal function (see section 4.2).</p><p><strong>Paediatrics</strong></p><p>The serum half-life of cefuroxime has been shown to be substantially prolonged in neonates according to gestational age. However, in older infants (aged &gt;3 weeks) and in children, the serum half-life of 60 to 90 minutes is similar to that observed in adults.</p><p><strong>Renal impairment</strong></p><p>Cefuroxime is primarily excreted by the kidneys. As with all such antibiotics, in patients with markedly impaired renal function (i.e. C1<sub>cr</sub>&nbsp;&lt;20 mL/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section 4.2). Cefuroxime is effectively removed by haemodialysis and peritoneal dialysis.</p><p><strong>Hepatic impairment</strong></p><p>Since cefuroxime is primarily eliminated by the kidney, hepatic dysfunction is not expected to have an effect on the pharmacokinetics of cefuroxime.</p><p><strong>PK/PD relationship</strong></p><p>For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with&nbsp;<em>in vivo</em>&nbsp;efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T&gt;MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.</p><p>Gamma glutamyl transpeptidase activity in rat urine is inhibited by various cephalosporins; however, the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefuroxime is compatible with most commonly used intravenous fluids and electrolyte solutions.</p><p>The pH of 2.74% w/v sodium bicarbonate injection BP considerably affects the colour of solutions and therefore this solution is not recommended for the dilution of Cefuroxime. However, if required, for patients receiving sodium bicarbonate injection by infusion the Cefuroxime may be introduced into the tube of the giving set.</p><p>Cefuroxime should not be mixed in the syringe with aminoglycoside antibiotics.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>The reconstituted solutions should be used within 24 hours at room temperature when prepared in sterile water for injection, 0.9% sodium chloride, and 5% dextrose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; Clear glass vial sealed with rubber closure and flip-off aluminium seal with a printed label, one vial packed in a printed box along with a leaflet.</p><p>&sect; Clear glass vial sealed with rubber closure and flip-off aluminium seal with a printed label, 10 vials packed in a printed box along with a leaflet.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Instructions for constitution</u></strong></p><p><strong>Intramuscular:</strong> Add 3mL Water for Injection to 750mg <strong>Cefuzime</strong>. Shake gently to produce an opaque suspension.</p><p><strong>Intravenous:</strong> Dissolve <strong>Cefuzime </strong>in Water for Injection using at least 8mL for 750mg. For short intravenous infusion (e.g. up to 30 minutes), 750mg may be dissolved in 50ml Water for Injection. These solutions may be given directly into the vein or introduced into the tubing of the giving set if the patient is receiving parenteral fluids.</p><p><strong><u>Compatibility</u></strong></p><p>Cefuroxime sodium is compatible with the following infusion fluids. It will retain potency for up to 24 hours at room temperature in:</p><p>&sect; Sterile water for injection</p><p>&sect; Sodium Chloride Injection 0.9%</p><p>&sect; 5% Dextrose Injection</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04. June. 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>